ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,701 to 4,720 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
A+AVD vs ABVD: serious adverse events284 of 662

178 of 659

15.9 points

10.8 to 20.9

1,321NCT01712490

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Proactive Outreach vs Usual Care: Number of Participants Self-Reporting 7-Day Abstinence From Cigarettes119 of 620

96 of 701

5.5 points

1.5 to 9.5

1,321NCT01737281

Proactive Outreach for Smokers in VA Mental Health

Q/LAIV (MEDI3250) vs All FluMist: The Number of Serosusceptible Participants Within Each Treatment Arm Who Experience A/H1N1 Strain-specific Seroresponse Post Dose.59 of 889

30 of 429

-0.4 points

-3.5 to 2.4

1,318NCT00860067

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Q/LAIV (MEDI3250) vs All FluMist: The Number of Serosusceptible Participants Within Each Treatment Arm Who Achieved a A/H1N1 Strain-specific HAI Antibody Titer ≥ 32 Post Dose.17 of 889

5 of 429

0.7 points

-0.9 to 2.1

1,318NCT00860067

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Phase I vs Phase II: deaths from any cause2 of 847

1 of 470

0.0 points

-1.0 to 0.7

1,317NCT01643707

Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)

CPAP vs Surfactant: Survival Without Bronchopulmonary Dysplasia (BPD)346 of 663

320 of 653

3.2 points

-2.2 to 8.6

1,316NCT00233324

Surfactant Positive Airway Pressure and Pulse Oximetry Trial

Rilonacept 160 mg vs Placebo: serious adverse events31 of 985

13 of 330

-0.8 points

-3.6 to 1.3

1,315NCT00856206

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

CT-P59 40 mg/kg Group (Part 2) vs Placebo Group (Part 2): Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection up to Day 28 in All Randomized Patients (Part 2)16 of 656

53 of 659

-5.6 points

-8.1 to -3.2

1,315NCT04602000

A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection

Clostridium Difficile Vaccine (Pooled Lots) vs Placebo: deaths from any cause2 of 983

2 of 331

-0.4 points

-2.0 to 0.3

1,314NCT03579459

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

Clostridium Difficile Vaccine (Pooled Lots) vs Placebo: serious adverse events41 of 983

15 of 331

-0.4 points

-3.4 to 1.9

1,314NCT03579459

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): deaths from any cause593 of 657

570 of 656

3.4 points

-0.1 to 6.8

1,313NCT00946712

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): deaths from any cause271 of 647

280 of 665

-0.2 points

-5.5 to 5.1

1,312NCT00063999

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): serious adverse events217 of 647

156 of 665

10.1 points

5.2 to 14.9

1,312NCT00063999

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

PR5I vs INFANRIX™ Hexa: serious adverse events6 of 653

10 of 659

-0.6 points

-1.9 to 0.7

1,312NCT01480258

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Treatment vs Placebo: deaths from any cause1 of 658

1 of 654

-0.0 points

-0.7 to 0.7

1,312NCT04308668

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

Treatment vs Placebo: serious adverse events6 of 658

11 of 654

-0.8 points

-2.2 to 0.5

1,312NCT04308668

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): Number of Participants Who Has Experienced at Least One Toxicity (Defined as a Grade 3 or Higher Adverse Event Deemed at Least Possibly Related to Treatment)167 of 657

287 of 654

-18.5 points

-23.4 to -13.4

1,311NCT01949337

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): deaths from any cause372 of 657

339 of 654

4.8 points

-0.6 to 10.1

1,311NCT01949337

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Arm A: (Enzalutamide) vs Arm B: (Enzalutamide, Abiraterone, Prednisone): serious adverse events232 of 657

269 of 654

-5.8 points

-11.0 to -0.6

1,311NCT01949337

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

PF-07321332 300 mg + Ritonavir 100 mg vs Placebo: Number of Participants With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT Population507 of 666

483 of 645

1.2 points

-3.4 to 5.9

1,311NCT04960202

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=236"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=236

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01712490-sae",
        "title": "A+AVD vs ABVD: serious adverse events",
        "summary": "284 of 662 against 178 of 659; risk difference 15.9 points, 95% interval 10.8 to 20.9; NCT01712490, A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma",
        "record": "/library/comparisons/NCT01712490-sae",
        "nct_id": "NCT01712490",
        "kind": "serious-adverse-events",
        "participants": 1321,
        "risk_difference": {
          "value": 0.15889679960023656,
          "lower": 0.10772020091088992,
          "upper": 0.2089003984637372
        },
        "group_1": "284 of 662",
        "group_2": "178 of 659",
        "difference": "15.9 points",
        "interval": "10.8 to 20.9",
        "trial_title": "A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma"
      },
      {
        "id": "NCT01737281-70004451",
        "title": "Proactive Outreach vs Usual Care: Number of Participants Self-Reporting 7-Day Abstinence From Cigarettes",
        "summary": "119 of 620 against 96 of 701; risk difference 5.5 points, 95% interval 1.5 to 9.5; NCT01737281, Proactive Outreach for Smokers in VA Mental Health",
        "record": "/library/comparisons/NCT01737281-70004451",
        "nct_id": "NCT01737281",
        "kind": "outcome",
        "participants": 1321,
        "risk_difference": {
          "value": 0.05498826561133863,
          "lower": 0.015019421103793812,
          "upper": 0.09537339112701917
        },
        "group_1": "119 of 620",
        "group_2": "96 of 701",
        "difference": "5.5 points",
        "interval": "1.5 to 9.5",
        "trial_title": "Proactive Outreach for Smokers in VA Mental Health"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=237",
  "request_id": "Vfmb-COkqCOOFAJV"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?